Abstract
Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have